Solid Phase Extraction (SPE)
HIV antibody study results announced
Sep 28 2011
The findings of a Phase II study of ibalizumab, raise more questions than answers but the researchers involved claimed that it definitely holds potential for HIV treatment veterans in need of novel therapies.
Developed by TaiMed Biologics, a biotechnology company with research facilities in Taiwan and Irvine, California, ibalizumab is an experimental entry inhibitor containing genetically engineered antibodies that bind to the CD4 receptor on CD4 cells.
Following this process HIV cannot connect to the surface of CD4, preventing the virus from infecting healthy cells.
The investigation resulted in no drug-related deaths, serious side effects or discontinuations, however some anomalies were noted.
Dr Stanley Lewis of TaiMed said that after 24 weeks of treatment, viral loads were reduced, with undetectable viral loads documented in 44 per cent of those in the 800 mg ibalizumab dose group, and 28 per cent in the 2,000mg dose group.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Sep 04 2024 Chiba, Tokyo, Japan